|
Vaccine Detail
rORFV-D1701-V-HAh5n (H5N1) |
Vaccine Information |
- Vaccine Name: rORFV-D1701-V-HAh5n (H5N1)
- Target Pathogen: Influenza virus
- Target Disease: Influenza (flu)
- Vaccine Ontology ID: VO_0004765
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- Vector:
- Preparation: ORFV recombinants expressing the hemagglutinin (HA) or nucleoprotein (NP) of the highly pathogenic avian influenza virus (HPAIV) H5N1 (Rohde et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
|
Host Response |
Mouse Response
- Vaccination Protocol: The mice were immunized with varying doses of D1701-V-HAh5n (Rohde et al., 2013).
- Vaccine Immune Response Type: VO_0000286
- Challenge Protocol: Mice were instilled intranasally (i.n.) under anaesthesia [20] using 50 µl of the indicated mouse 50% lethal dose (MLD50) of HPAIV. For BALB/c mice 1× MLD50 corresponded to 7×10^1 plaque-forming units (pfu) of strain MB1, 2×10^1 pfu of strain SN1 and 1×10^4 pfu of strain PR8. For C57BL/6 mice 2×10^3 pfu of strain MB1, 1.4×103^ pfu of strain PR8 matched to 1× MLD50 (Rohde et al., 2013).
- Efficacy: Despite adequate expression of NP, the recombinant D1701-V-NPh5 completely failed to protect mice from lethal challenge. However, the H5 HA-expressing recombinant D1701-V-HAh5n mediated solid protection in a dose-dependent manner. Two intramuscular (i.m.) injections of the HA-expressing recombinant protected all animals from lethal HPAIV infection without loss of body weight. Notably, the immunized mice resisted cross-clade H5N1 and heterologous H1N1 (strain PR8) influenza virus challenge (Rohde et al., 2013).
|
References |
Rohde et al., 2013: Rohde J, Amann R, Rziha HJ. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus. PloS one. 2013; 8(12); e83802. [PubMed: 24376753].
|
|